Changchun High-Tech Industry (SHE:000661) secured Chinese regulatory approval to begin clinical trials for fuxinqibai injection.
The monoclonal antibody is indicated for reducing acute gout flares during early urate-lowering therapy, according to a Wednesday filing with the Shenzhen bourse.
Shares of the drug manufacturer were down 2% in recent trade.